nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Gefitinib—lung cancer	0.32	1	CrCtD
Afatinib—Vandetanib—Erlotinib—lung cancer	0.082	0.406	CrCrCtD
Afatinib—ERBB2—lung cancer	0.0799	0.51	CbGaD
Afatinib—Vandetanib—Gefitinib—lung cancer	0.0731	0.361	CrCrCtD
Afatinib—Gefitinib—Erlotinib—lung cancer	0.0471	0.233	CrCrCtD
Afatinib—EGFR—lung cancer	0.0378	0.241	CbGaD
Afatinib—ABCG2—lung cancer	0.0276	0.176	CbGaD
Afatinib—IRAK1—Gefitinib—lung cancer	0.0231	0.106	CbGbCtD
Afatinib—HIPK4—Gefitinib—lung cancer	0.0204	0.0934	CbGbCtD
Afatinib—EPHA6—Gefitinib—lung cancer	0.0204	0.0934	CbGbCtD
Afatinib—EGFR—Gefitinib—lung cancer	0.0183	0.084	CbGbCtD
Afatinib—IRAK1—Crizotinib—lung cancer	0.0141	0.0648	CbGbCtD
Afatinib—BLK—Crizotinib—lung cancer	0.0125	0.0573	CbGbCtD
Afatinib—EPHA6—Crizotinib—lung cancer	0.0125	0.0573	CbGbCtD
Afatinib—EPHA6—Erlotinib—lung cancer	0.0121	0.0552	CbGbCtD
Afatinib—HIPK4—Erlotinib—lung cancer	0.0121	0.0552	CbGbCtD
Afatinib—ABCB1—lung cancer	0.0115	0.0733	CbGaD
Afatinib—EGFR—Erlotinib—lung cancer	0.0108	0.0496	CbGbCtD
Afatinib—LCK—Crizotinib—lung cancer	0.0102	0.0468	CbGbCtD
Afatinib—ABL1—Crizotinib—lung cancer	0.00813	0.0372	CbGbCtD
Afatinib—ABL1—Erlotinib—lung cancer	0.00784	0.0359	CbGbCtD
Afatinib—EGFR—Docetaxel—lung cancer	0.00718	0.0329	CbGbCtD
Afatinib—ABCG2—Topotecan—lung cancer	0.00331	0.0152	CbGbCtD
Afatinib—ABCG2—Gefitinib—lung cancer	0.00303	0.0139	CbGbCtD
Afatinib—ABCG2—Teniposide—lung cancer	0.00294	0.0134	CbGbCtD
Afatinib—ABCG2—Erlotinib—lung cancer	0.00179	0.0082	CbGbCtD
Afatinib—ABCG2—Paclitaxel—lung cancer	0.00164	0.0075	CbGbCtD
Afatinib—ABCG2—Irinotecan—lung cancer	0.00162	0.0074	CbGbCtD
Afatinib—ABCG2—Cisplatin—lung cancer	0.00132	0.00604	CbGbCtD
Afatinib—ABCG2—Etoposide—lung cancer	0.0013	0.00593	CbGbCtD
Afatinib—ABCB1—Topotecan—lung cancer	0.00119	0.00547	CbGbCtD
Afatinib—ABCG2—Docetaxel—lung cancer	0.00119	0.00543	CbGbCtD
Afatinib—ABCB1—Gefitinib—lung cancer	0.00109	0.005	CbGbCtD
Afatinib—ABCG2—Doxorubicin—lung cancer	0.000883	0.00404	CbGbCtD
Afatinib—ABCG2—Methotrexate—lung cancer	0.000856	0.00392	CbGbCtD
Afatinib—ABCB1—Vinorelbine—lung cancer	0.000841	0.00385	CbGbCtD
Afatinib—ERBB2—mammary gland—lung cancer	0.000837	0.065	CbGeAlD
Afatinib—ERBB4—mammary gland—lung cancer	0.000837	0.065	CbGeAlD
Afatinib—DYRK1A—mammary gland—lung cancer	0.000805	0.0626	CbGeAlD
Afatinib—EGFR—mammary gland—lung cancer	0.000709	0.0551	CbGeAlD
Afatinib—ABCB1—Crizotinib—lung cancer	0.000669	0.00306	CbGbCtD
Afatinib—ABCB1—Gemcitabine—lung cancer	0.000654	0.003	CbGbCtD
Afatinib—ABCB1—Erlotinib—lung cancer	0.000646	0.00296	CbGbCtD
Afatinib—ABCB1—Paclitaxel—lung cancer	0.000591	0.00271	CbGbCtD
Afatinib—ABCB1—Irinotecan—lung cancer	0.000583	0.00267	CbGbCtD
Afatinib—ERBB4—respiratory system—lung cancer	0.000558	0.0433	CbGeAlD
Afatinib—ERBB2—respiratory system—lung cancer	0.000558	0.0433	CbGeAlD
Afatinib—DYRK1A—respiratory system—lung cancer	0.000537	0.0417	CbGeAlD
Afatinib—ABCB1—Vinblastine—lung cancer	0.000518	0.00237	CbGbCtD
Afatinib—ABCB1—Cisplatin—lung cancer	0.000475	0.00218	CbGbCtD
Afatinib—ABCB1—Etoposide—lung cancer	0.000467	0.00214	CbGbCtD
Afatinib—ERBB2—epithelium—lung cancer	0.000466	0.0362	CbGeAlD
Afatinib—ERBB4—epithelium—lung cancer	0.000466	0.0362	CbGeAlD
Afatinib—ABCB1—Docetaxel—lung cancer	0.000427	0.00196	CbGbCtD
Afatinib—ERBB4—cardiac atrium—lung cancer	0.000387	0.0301	CbGeAlD
Afatinib—ABL1—mammary gland—lung cancer	0.000351	0.0272	CbGeAlD
Afatinib—IRAK1—bronchus—lung cancer	0.000343	0.0267	CbGeAlD
Afatinib—LCK—bronchus—lung cancer	0.000335	0.026	CbGeAlD
Afatinib—PHKG2—lung—lung cancer	0.000329	0.0256	CbGeAlD
Afatinib—ABCB1—Doxorubicin—lung cancer	0.000319	0.00146	CbGbCtD
Afatinib—ABCB1—Methotrexate—lung cancer	0.000309	0.00141	CbGbCtD
Afatinib—LCK—trachea—lung cancer	0.000301	0.0233	CbGeAlD
Afatinib—ERBB4—lung—lung cancer	0.000296	0.023	CbGeAlD
Afatinib—ERBB2—lung—lung cancer	0.000296	0.023	CbGeAlD
Afatinib—BLK—lymph node—lung cancer	0.000295	0.0229	CbGeAlD
Afatinib—Vandetanib—AXL—lung cancer	0.00029	0.183	CrCbGaD
Afatinib—DYRK1A—lung—lung cancer	0.000285	0.0221	CbGeAlD
Afatinib—EGFR—lung—lung cancer	0.000251	0.0195	CbGeAlD
Afatinib—Vandetanib—FGR—lung cancer	0.000247	0.156	CrCbGaD
Afatinib—IRAK1—bone marrow—lung cancer	0.000244	0.019	CbGeAlD
Afatinib—LCK—bone marrow—lung cancer	0.000238	0.0185	CbGeAlD
Afatinib—DYRK1A—Topotecan—Irinotecan—lung cancer	0.000234	0.224	CbGdCrCtD
Afatinib—ABL1—respiratory system—lung cancer	0.000234	0.0181	CbGeAlD
Afatinib—PHKG2—lymph node—lung cancer	0.000225	0.0175	CbGeAlD
Afatinib—IRAK1—lung—lung cancer	0.000221	0.0172	CbGeAlD
Afatinib—LCK—lung—lung cancer	0.000216	0.0168	CbGeAlD
Afatinib—ERBB2—lymph node—lung cancer	0.000203	0.0157	CbGeAlD
Afatinib—DYRK1A—lymph node—lung cancer	0.000195	0.0151	CbGeAlD
Afatinib—ABL1—bronchus—lung cancer	0.000192	0.0149	CbGeAlD
Afatinib—ERBB2—Topotecan—Irinotecan—lung cancer	0.00018	0.172	CbGdCrCtD
Afatinib—Vandetanib—ERBB3—lung cancer	0.000176	0.111	CrCbGaD
Afatinib—ABL1—trachea—lung cancer	0.000173	0.0134	CbGeAlD
Afatinib—EGFR—lymph node—lung cancer	0.000172	0.0133	CbGeAlD
Afatinib—Gefitinib—ERBB3—lung cancer	0.000167	0.106	CrCbGaD
Afatinib—ABL1—cardiac atrium—lung cancer	0.000162	0.0126	CbGeAlD
Afatinib—IRAK1—lymph node—lung cancer	0.000151	0.0118	CbGeAlD
Afatinib—LCK—lymph node—lung cancer	0.000148	0.0115	CbGeAlD
Afatinib—ABL1—bone marrow—lung cancer	0.000137	0.0106	CbGeAlD
Afatinib—ERBB2—Podofilox—Teniposide—lung cancer	0.000137	0.131	CbGdCrCtD
Afatinib—ABL1—Topotecan—Irinotecan—lung cancer	0.000135	0.129	CbGdCrCtD
Afatinib—ABL1—lung—lung cancer	0.000124	0.00964	CbGeAlD
Afatinib—Vandetanib—SRC—lung cancer	0.000117	0.0742	CrCbGaD
Afatinib—Vandetanib—KDR—lung cancer	0.00011	0.0697	CrCbGaD
Afatinib—Vandetanib—VEGFA—lung cancer	9.35e-05	0.0591	CrCbGaD
Afatinib—ABCG2—bone marrow—lung cancer	8.64e-05	0.00671	CbGeAlD
Afatinib—ABL1—lymph node—lung cancer	8.48e-05	0.00659	CbGeAlD
Afatinib—ERBB2—Podofilox—Etoposide—lung cancer	8.13e-05	0.0776	CbGdCrCtD
Afatinib—Vandetanib—EGFR—lung cancer	7.89e-05	0.0498	CrCbGaD
Afatinib—ABCG2—lung—lung cancer	7.82e-05	0.00608	CbGeAlD
Afatinib—Gefitinib—EGFR—lung cancer	7.5e-05	0.0474	CrCbGaD
Afatinib—ABCB1—respiratory system—lung cancer	7.27e-05	0.00564	CbGeAlD
Afatinib—ABCB1—epithelium—lung cancer	6.07e-05	0.00472	CbGeAlD
Afatinib—Vandetanib—ABCG2—lung cancer	5.76e-05	0.0364	CrCbGaD
Afatinib—Gefitinib—ABCG2—lung cancer	5.48e-05	0.0346	CrCbGaD
Afatinib—ABCB1—trachea—lung cancer	5.37e-05	0.00417	CbGeAlD
Afatinib—ABCG2—lymph node—lung cancer	5.35e-05	0.00416	CbGeAlD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—lung cancer	5.1e-05	0.0487	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—lung cancer	5.1e-05	0.0487	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—lung cancer	5.1e-05	0.0487	CbGdCrCtD
Afatinib—Gefitinib—CYP1A1—lung cancer	4.29e-05	0.0271	CrCbGaD
Afatinib—ABCB1—bone marrow—lung cancer	4.26e-05	0.00331	CbGeAlD
Afatinib—ERBB2—Epirubicin—Doxorubicin—lung cancer	3.92e-05	0.0375	CbGdCrCtD
Afatinib—ABCB1—lung—lung cancer	3.86e-05	0.003	CbGeAlD
Afatinib—Diarrhoea—Vinblastine—lung cancer	3e-05	0.000723	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—lung cancer	3e-05	0.000723	CcSEcCtD
Afatinib—Infection—Irinotecan—lung cancer	2.99e-05	0.00072	CcSEcCtD
Afatinib—Pruritus—Erlotinib—lung cancer	2.98e-05	0.000719	CcSEcCtD
Afatinib—Back pain—Etoposide—lung cancer	2.96e-05	0.000714	CcSEcCtD
Afatinib—Nervous system disorder—Irinotecan—lung cancer	2.95e-05	0.00071	CcSEcCtD
Afatinib—Muscle spasms—Etoposide—lung cancer	2.95e-05	0.00071	CcSEcCtD
Afatinib—Dysgeusia—Paclitaxel—lung cancer	2.94e-05	0.000709	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—lung cancer	2.93e-05	0.028	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—lung cancer	2.93e-05	0.028	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—lung cancer	2.93e-05	0.028	CbGdCrCtD
Afatinib—Diarrhoea—Topotecan—lung cancer	2.92e-05	0.000703	CcSEcCtD
Afatinib—Infection—Gemcitabine—lung cancer	2.91e-05	0.000701	CcSEcCtD
Afatinib—Back pain—Paclitaxel—lung cancer	2.91e-05	0.0007	CcSEcCtD
Afatinib—Dizziness—Vinblastine—lung cancer	2.9e-05	0.000699	CcSEcCtD
Afatinib—Urinary tract disorder—Docetaxel—lung cancer	2.89e-05	0.000696	CcSEcCtD
Afatinib—Muscle spasms—Paclitaxel—lung cancer	2.89e-05	0.000696	CcSEcCtD
Afatinib—Diarrhoea—Erlotinib—lung cancer	2.88e-05	0.000695	CcSEcCtD
Afatinib—Body temperature increased—Vinorelbine—lung cancer	2.88e-05	0.000694	CcSEcCtD
Afatinib—Connective tissue disorder—Docetaxel—lung cancer	2.87e-05	0.000693	CcSEcCtD
Afatinib—Nervous system disorder—Gemcitabine—lung cancer	2.87e-05	0.000692	CcSEcCtD
Afatinib—Urethral disorder—Docetaxel—lung cancer	2.87e-05	0.000691	CcSEcCtD
Afatinib—Skin disorder—Gemcitabine—lung cancer	2.84e-05	0.000685	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	2.83e-05	0.000681	CcSEcCtD
Afatinib—Dizziness—Topotecan—lung cancer	2.82e-05	0.000679	CcSEcCtD
Afatinib—Vomiting—Vinblastine—lung cancer	2.79e-05	0.000672	CcSEcCtD
Afatinib—Dizziness—Erlotinib—lung cancer	2.79e-05	0.000672	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—lung cancer	2.77e-05	0.000668	CcSEcCtD
Afatinib—Headache—Vinblastine—lung cancer	2.75e-05	0.000662	CcSEcCtD
Afatinib—Eye disorder—Docetaxel—lung cancer	2.73e-05	0.000659	CcSEcCtD
Afatinib—Insomnia—Irinotecan—lung cancer	2.72e-05	0.000655	CcSEcCtD
Afatinib—Infection—Cisplatin—lung cancer	2.71e-05	0.000653	CcSEcCtD
Afatinib—Vomiting—Topotecan—lung cancer	2.71e-05	0.000653	CcSEcCtD
Afatinib—Rash—Topotecan—lung cancer	2.69e-05	0.000647	CcSEcCtD
Afatinib—Dermatitis—Topotecan—lung cancer	2.68e-05	0.000647	CcSEcCtD
Afatinib—Vomiting—Erlotinib—lung cancer	2.68e-05	0.000646	CcSEcCtD
Afatinib—Dyspnoea—Irinotecan—lung cancer	2.68e-05	0.000646	CcSEcCtD
Afatinib—Nervous system disorder—Cisplatin—lung cancer	2.68e-05	0.000645	CcSEcCtD
Afatinib—Cough—Etoposide—lung cancer	2.67e-05	0.000644	CcSEcCtD
Afatinib—Headache—Topotecan—lung cancer	2.67e-05	0.000643	CcSEcCtD
Afatinib—Rash—Erlotinib—lung cancer	2.66e-05	0.000641	CcSEcCtD
Afatinib—Dermatitis—Erlotinib—lung cancer	2.66e-05	0.00064	CcSEcCtD
Afatinib—Skin disorder—Cisplatin—lung cancer	2.65e-05	0.000639	CcSEcCtD
Afatinib—Insomnia—Gemcitabine—lung cancer	2.65e-05	0.000638	CcSEcCtD
Afatinib—Dyspepsia—Irinotecan—lung cancer	2.65e-05	0.000638	CcSEcCtD
Afatinib—Headache—Erlotinib—lung cancer	2.64e-05	0.000636	CcSEcCtD
Afatinib—ABCB1—lymph node—lung cancer	2.64e-05	0.00205	CbGeAlD
Afatinib—Mediastinal disorder—Docetaxel—lung cancer	2.64e-05	0.000635	CcSEcCtD
Afatinib—Cough—Paclitaxel—lung cancer	2.62e-05	0.000632	CcSEcCtD
Afatinib—Asthenia—Vinorelbine—lung cancer	2.62e-05	0.00063	CcSEcCtD
Afatinib—Decreased appetite—Irinotecan—lung cancer	2.61e-05	0.00063	CcSEcCtD
Afatinib—Dyspnoea—Gemcitabine—lung cancer	2.61e-05	0.000629	CcSEcCtD
Afatinib—Nausea—Vinblastine—lung cancer	2.61e-05	0.000628	CcSEcCtD
Afatinib—Gastrointestinal disorder—Irinotecan—lung cancer	2.6e-05	0.000625	CcSEcCtD
Afatinib—Fatigue—Irinotecan—lung cancer	2.59e-05	0.000625	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	2.59e-05	0.000624	CcSEcCtD
Afatinib—Alopecia—Docetaxel—lung cancer	2.59e-05	0.000623	CcSEcCtD
Afatinib—Pruritus—Vinorelbine—lung cancer	2.58e-05	0.000621	CcSEcCtD
Afatinib—Constipation—Irinotecan—lung cancer	2.57e-05	0.000619	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—lung cancer	2.56e-05	0.000618	CcSEcCtD
Afatinib—Malnutrition—Docetaxel—lung cancer	2.55e-05	0.000614	CcSEcCtD
Afatinib—Decreased appetite—Gemcitabine—lung cancer	2.55e-05	0.000613	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	2.54e-05	0.000612	CcSEcCtD
Afatinib—Nausea—Topotecan—lung cancer	2.53e-05	0.00061	CcSEcCtD
Afatinib—Gastrointestinal disorder—Gemcitabine—lung cancer	2.53e-05	0.000609	CcSEcCtD
Afatinib—Fatigue—Gemcitabine—lung cancer	2.53e-05	0.000608	CcSEcCtD
Afatinib—Vandetanib—ALB—lung cancer	2.51e-05	0.0159	CrCbGaD
Afatinib—Constipation—Gemcitabine—lung cancer	2.5e-05	0.000603	CcSEcCtD
Afatinib—Nausea—Erlotinib—lung cancer	2.5e-05	0.000603	CcSEcCtD
Afatinib—Diarrhoea—Vinorelbine—lung cancer	2.49e-05	0.000601	CcSEcCtD
Afatinib—Dysgeusia—Docetaxel—lung cancer	2.49e-05	0.000601	CcSEcCtD
Afatinib—Infection—Etoposide—lung cancer	2.48e-05	0.000599	CcSEcCtD
Afatinib—Back pain—Docetaxel—lung cancer	2.46e-05	0.000594	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—lung cancer	2.45e-05	0.000591	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—lung cancer	2.45e-05	0.00059	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—lung cancer	2.45e-05	0.00059	CcSEcCtD
Afatinib—Infection—Paclitaxel—lung cancer	2.44e-05	0.000587	CcSEcCtD
Afatinib—Dyspnoea—Cisplatin—lung cancer	2.43e-05	0.000586	CcSEcCtD
Afatinib—Skin disorder—Etoposide—lung cancer	2.43e-05	0.000585	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—lung cancer	2.42e-05	0.000583	CcSEcCtD
Afatinib—Dizziness—Vinorelbine—lung cancer	2.41e-05	0.000581	CcSEcCtD
Afatinib—Nervous system disorder—Paclitaxel—lung cancer	2.4e-05	0.000579	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—lung cancer	2.4e-05	0.000579	CcSEcCtD
Afatinib—Gefitinib—ALB—lung cancer	2.39e-05	0.0151	CrCbGaD
Afatinib—Skin disorder—Paclitaxel—lung cancer	2.38e-05	0.000574	CcSEcCtD
Afatinib—Body temperature increased—Irinotecan—lung cancer	2.38e-05	0.000573	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	2.38e-05	0.000573	CcSEcCtD
Afatinib—Decreased appetite—Cisplatin—lung cancer	2.37e-05	0.000572	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—lung cancer	2.36e-05	0.000569	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—lung cancer	2.36e-05	0.000569	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cisplatin—lung cancer	2.36e-05	0.000568	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—lung cancer	2.35e-05	0.000566	CcSEcCtD
Afatinib—Infestation—Methotrexate—lung cancer	2.35e-05	0.000566	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—lung cancer	2.33e-05	0.000561	CcSEcCtD
Afatinib—Vomiting—Vinorelbine—lung cancer	2.32e-05	0.000558	CcSEcCtD
Afatinib—Body temperature increased—Gemcitabine—lung cancer	2.32e-05	0.000558	CcSEcCtD
Afatinib—Renal failure—Methotrexate—lung cancer	2.31e-05	0.000556	CcSEcCtD
Afatinib—Rash—Vinorelbine—lung cancer	2.3e-05	0.000554	CcSEcCtD
Afatinib—Dermatitis—Vinorelbine—lung cancer	2.3e-05	0.000553	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—lung cancer	2.29e-05	0.000552	CcSEcCtD
Afatinib—Headache—Vinorelbine—lung cancer	2.28e-05	0.00055	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—lung cancer	2.28e-05	0.00055	CcSEcCtD
Afatinib—Gefitinib—ABCB1—lung cancer	2.28e-05	0.0144	CrCbGaD
Afatinib—Dyspnoea—Etoposide—lung cancer	2.23e-05	0.000537	CcSEcCtD
Afatinib—Cough—Docetaxel—lung cancer	2.22e-05	0.000535	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—lung cancer	2.22e-05	0.000535	CcSEcCtD
Afatinib—Insomnia—Paclitaxel—lung cancer	2.22e-05	0.000534	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—lung cancer	2.22e-05	0.000534	CcSEcCtD
Afatinib—Dyspnoea—Paclitaxel—lung cancer	2.19e-05	0.000527	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—lung cancer	2.17e-05	0.000524	CcSEcCtD
Afatinib—Nausea—Vinorelbine—lung cancer	2.17e-05	0.000522	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—lung cancer	2.16e-05	0.00052	CcSEcCtD
Afatinib—Dyspepsia—Paclitaxel—lung cancer	2.16e-05	0.00052	CcSEcCtD
Afatinib—Body temperature increased—Cisplatin—lung cancer	2.16e-05	0.00052	CcSEcCtD
Afatinib—Asthenia—Irinotecan—lung cancer	2.16e-05	0.00052	CcSEcCtD
Afatinib—Fatigue—Etoposide—lung cancer	2.16e-05	0.00052	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	2.15e-05	0.000519	CcSEcCtD
Afatinib—Constipation—Etoposide—lung cancer	2.14e-05	0.000515	CcSEcCtD
Afatinib—Decreased appetite—Paclitaxel—lung cancer	2.13e-05	0.000514	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—lung cancer	2.12e-05	0.000511	CcSEcCtD
Afatinib—Gastrointestinal disorder—Paclitaxel—lung cancer	2.12e-05	0.00051	CcSEcCtD
Afatinib—Fatigue—Paclitaxel—lung cancer	2.11e-05	0.000509	CcSEcCtD
Afatinib—Asthenia—Gemcitabine—lung cancer	2.1e-05	0.000506	CcSEcCtD
Afatinib—Constipation—Paclitaxel—lung cancer	2.1e-05	0.000505	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—lung cancer	2.08e-05	0.000502	CcSEcCtD
Afatinib—Pruritus—Gemcitabine—lung cancer	2.07e-05	0.000499	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—lung cancer	2.07e-05	0.000498	CcSEcCtD
Afatinib—Infection—Docetaxel—lung cancer	2.06e-05	0.000498	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—lung cancer	2.06e-05	0.000497	CcSEcCtD
Afatinib—Diarrhoea—Irinotecan—lung cancer	2.06e-05	0.000496	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—lung cancer	2.05e-05	0.000493	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—lung cancer	2.04e-05	0.000491	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—lung cancer	2.03e-05	0.00049	CcSEcCtD
Afatinib—Infestation—Doxorubicin—lung cancer	2.03e-05	0.00049	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—lung cancer	2.02e-05	0.000486	CcSEcCtD
Afatinib—Diarrhoea—Gemcitabine—lung cancer	2e-05	0.000483	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—lung cancer	2e-05	0.000482	CcSEcCtD
Afatinib—Dizziness—Irinotecan—lung cancer	1.99e-05	0.000479	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—lung cancer	1.98e-05	0.000478	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—lung cancer	1.98e-05	0.000476	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—lung cancer	1.98e-05	0.000476	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—lung cancer	1.98e-05	0.000476	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—lung cancer	1.97e-05	0.000475	CcSEcCtD
Afatinib—Asthenia—Cisplatin—lung cancer	1.96e-05	0.000472	CcSEcCtD
Afatinib—Body temperature increased—Paclitaxel—lung cancer	1.94e-05	0.000467	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—lung cancer	1.92e-05	0.000463	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—lung cancer	1.92e-05	0.000462	CcSEcCtD
Afatinib—Vomiting—Irinotecan—lung cancer	1.91e-05	0.000461	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—lung cancer	1.9e-05	0.000458	CcSEcCtD
Afatinib—Rash—Irinotecan—lung cancer	1.9e-05	0.000457	CcSEcCtD
Afatinib—Dermatitis—Irinotecan—lung cancer	1.89e-05	0.000456	CcSEcCtD
Afatinib—Headache—Irinotecan—lung cancer	1.88e-05	0.000454	CcSEcCtD
Afatinib—Insomnia—Docetaxel—lung cancer	1.88e-05	0.000453	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—lung cancer	1.87e-05	0.00045	CcSEcCtD
Afatinib—Alopecia—Methotrexate—lung cancer	1.86e-05	0.000449	CcSEcCtD
Afatinib—Vomiting—Gemcitabine—lung cancer	1.86e-05	0.000449	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—lung cancer	1.85e-05	0.000446	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—lung cancer	1.85e-05	0.000445	CcSEcCtD
Afatinib—Rash—Gemcitabine—lung cancer	1.85e-05	0.000445	CcSEcCtD
Afatinib—Dermatitis—Gemcitabine—lung cancer	1.84e-05	0.000445	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—lung cancer	1.84e-05	0.000442	CcSEcCtD
Afatinib—Headache—Gemcitabine—lung cancer	1.83e-05	0.000442	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—lung cancer	1.83e-05	0.000441	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—lung cancer	1.81e-05	0.000435	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—lung cancer	1.8e-05	0.000434	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—lung cancer	1.8e-05	0.000433	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—lung cancer	1.79e-05	0.000432	CcSEcCtD
Afatinib—Asthenia—Etoposide—lung cancer	1.79e-05	0.000432	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—lung cancer	1.79e-05	0.000432	CcSEcCtD
Afatinib—Fatigue—Docetaxel—lung cancer	1.79e-05	0.000432	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—lung cancer	1.79e-05	0.000431	CcSEcCtD
Afatinib—Nausea—Irinotecan—lung cancer	1.79e-05	0.00043	CcSEcCtD
Afatinib—Constipation—Docetaxel—lung cancer	1.78e-05	0.000428	CcSEcCtD
Afatinib—Back pain—Methotrexate—lung cancer	1.78e-05	0.000428	CcSEcCtD
Afatinib—Pruritus—Etoposide—lung cancer	1.77e-05	0.000426	CcSEcCtD
Afatinib—Asthenia—Paclitaxel—lung cancer	1.76e-05	0.000424	CcSEcCtD
Afatinib—Nausea—Gemcitabine—lung cancer	1.74e-05	0.000419	CcSEcCtD
Afatinib—Vomiting—Cisplatin—lung cancer	1.74e-05	0.000418	CcSEcCtD
Afatinib—Pruritus—Paclitaxel—lung cancer	1.73e-05	0.000418	CcSEcCtD
Afatinib—Rash—Cisplatin—lung cancer	1.72e-05	0.000415	CcSEcCtD
Afatinib—Dermatitis—Cisplatin—lung cancer	1.72e-05	0.000414	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—lung cancer	1.71e-05	0.000412	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—lung cancer	1.71e-05	0.000411	CcSEcCtD
Afatinib—Diarrhoea—Paclitaxel—lung cancer	1.68e-05	0.000404	CcSEcCtD
Afatinib—Dizziness—Etoposide—lung cancer	1.65e-05	0.000398	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—lung cancer	1.65e-05	0.000396	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—lung cancer	1.64e-05	0.000396	CcSEcCtD
Afatinib—Dizziness—Paclitaxel—lung cancer	1.62e-05	0.000391	CcSEcCtD
Afatinib—Nausea—Cisplatin—lung cancer	1.62e-05	0.000391	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—lung cancer	1.61e-05	0.000389	CcSEcCtD
Afatinib—Cough—Methotrexate—lung cancer	1.6e-05	0.000386	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—lung cancer	1.6e-05	0.000385	CcSEcCtD
Afatinib—Vomiting—Etoposide—lung cancer	1.59e-05	0.000383	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—lung cancer	1.59e-05	0.000383	CcSEcCtD
Afatinib—Rash—Etoposide—lung cancer	1.58e-05	0.00038	CcSEcCtD
Afatinib—Dermatitis—Etoposide—lung cancer	1.58e-05	0.00038	CcSEcCtD
Afatinib—Headache—Etoposide—lung cancer	1.57e-05	0.000377	CcSEcCtD
Afatinib—Vomiting—Paclitaxel—lung cancer	1.56e-05	0.000376	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—lung cancer	1.56e-05	0.000375	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.55e-05	0.000374	CcSEcCtD
Afatinib—Rash—Paclitaxel—lung cancer	1.55e-05	0.000373	CcSEcCtD
Afatinib—Dermatitis—Paclitaxel—lung cancer	1.54e-05	0.000372	CcSEcCtD
Afatinib—Back pain—Doxorubicin—lung cancer	1.54e-05	0.00037	CcSEcCtD
Afatinib—Headache—Paclitaxel—lung cancer	1.54e-05	0.00037	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—lung cancer	1.53e-05	0.000368	CcSEcCtD
Afatinib—Asthenia—Docetaxel—lung cancer	1.49e-05	0.000359	CcSEcCtD
Afatinib—Infection—Methotrexate—lung cancer	1.49e-05	0.000359	CcSEcCtD
Afatinib—Nausea—Etoposide—lung cancer	1.49e-05	0.000358	CcSEcCtD
Afatinib—Pruritus—Docetaxel—lung cancer	1.47e-05	0.000354	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—lung cancer	1.47e-05	0.000354	CcSEcCtD
Afatinib—Nausea—Paclitaxel—lung cancer	1.46e-05	0.000351	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—lung cancer	1.46e-05	0.000351	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—lung cancer	1.42e-05	0.000343	CcSEcCtD
Afatinib—Cough—Doxorubicin—lung cancer	1.39e-05	0.000334	CcSEcCtD
Afatinib—Dizziness—Docetaxel—lung cancer	1.37e-05	0.000331	CcSEcCtD
Afatinib—Insomnia—Methotrexate—lung cancer	1.35e-05	0.000326	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.34e-05	0.000324	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—lung cancer	1.34e-05	0.000322	CcSEcCtD
Afatinib—Vomiting—Docetaxel—lung cancer	1.32e-05	0.000318	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—lung cancer	1.32e-05	0.000318	CcSEcCtD
Afatinib—Rash—Docetaxel—lung cancer	1.31e-05	0.000316	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—lung cancer	1.31e-05	0.000315	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—lung cancer	1.3e-05	0.000314	CcSEcCtD
Afatinib—Headache—Docetaxel—lung cancer	1.3e-05	0.000314	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—lung cancer	1.29e-05	0.000312	CcSEcCtD
Afatinib—Fatigue—Methotrexate—lung cancer	1.29e-05	0.000311	CcSEcCtD
Afatinib—Infection—Doxorubicin—lung cancer	1.29e-05	0.00031	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—lung cancer	1.27e-05	0.000306	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—lung cancer	1.26e-05	0.000304	CcSEcCtD
Afatinib—Nausea—Docetaxel—lung cancer	1.23e-05	0.000297	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—lung cancer	1.18e-05	0.000285	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—lung cancer	1.17e-05	0.000283	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—lung cancer	1.16e-05	0.000279	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—lung cancer	1.14e-05	0.000275	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—lung cancer	1.13e-05	0.000272	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—lung cancer	1.12e-05	0.00027	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—lung cancer	1.12e-05	0.000269	CcSEcCtD
Afatinib—Constipation—Doxorubicin—lung cancer	1.11e-05	0.000267	CcSEcCtD
Afatinib—Asthenia—Methotrexate—lung cancer	1.07e-05	0.000259	CcSEcCtD
Afatinib—Pruritus—Methotrexate—lung cancer	1.06e-05	0.000255	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—lung cancer	1.03e-05	0.000247	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—lung cancer	1.02e-05	0.000247	CcSEcCtD
Afatinib—Dizziness—Methotrexate—lung cancer	9.91e-06	0.000239	CcSEcCtD
Afatinib—Vomiting—Methotrexate—lung cancer	9.52e-06	0.000229	CcSEcCtD
Afatinib—Rash—Methotrexate—lung cancer	9.44e-06	0.000228	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—lung cancer	9.44e-06	0.000227	CcSEcCtD
Afatinib—Headache—Methotrexate—lung cancer	9.38e-06	0.000226	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—lung cancer	9.31e-06	0.000224	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—lung cancer	9.18e-06	0.000221	CcSEcCtD
Afatinib—Nausea—Methotrexate—lung cancer	8.9e-06	0.000214	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—lung cancer	8.87e-06	0.000214	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—lung cancer	8.58e-06	0.000207	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—lung cancer	8.25e-06	0.000199	CcSEcCtD
Afatinib—Rash—Doxorubicin—lung cancer	8.18e-06	0.000197	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—lung cancer	8.17e-06	0.000197	CcSEcCtD
Afatinib—Headache—Doxorubicin—lung cancer	8.13e-06	0.000196	CcSEcCtD
Afatinib—Nausea—Doxorubicin—lung cancer	7.7e-06	0.000186	CcSEcCtD
Afatinib—EGFR—Disease—RAF1—lung cancer	6.58e-07	1.44e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	6.57e-07	1.43e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CG—lung cancer	6.56e-07	1.43e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—lung cancer	6.54e-07	1.43e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—SRC—lung cancer	6.53e-07	1.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR1—lung cancer	6.52e-07	1.42e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—lung cancer	6.52e-07	1.42e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—lung cancer	6.51e-07	1.42e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—lung cancer	6.49e-07	1.42e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—lung cancer	6.47e-07	1.41e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—lung cancer	6.47e-07	1.41e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—lung cancer	6.45e-07	1.41e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—lung cancer	6.44e-07	1.41e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOA1—lung cancer	6.43e-07	1.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTOR—lung cancer	6.43e-07	1.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CB—lung cancer	6.43e-07	1.4e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—lung cancer	6.42e-07	1.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—lung cancer	6.41e-07	1.4e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—lung cancer	6.39e-07	1.4e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—lung cancer	6.37e-07	1.39e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—lung cancer	6.37e-07	1.39e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—lung cancer	6.37e-07	1.39e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—lung cancer	6.36e-07	1.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—lung cancer	6.35e-07	1.39e-05	CbGpPWpGaD
Afatinib—LCK—Disease—RAF1—lung cancer	6.34e-07	1.38e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2E1—lung cancer	6.3e-07	1.38e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—lung cancer	6.29e-07	1.37e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—lung cancer	6.28e-07	1.37e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—lung cancer	6.28e-07	1.37e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—POMC—lung cancer	6.24e-07	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—lung cancer	6.24e-07	1.36e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NQO1—lung cancer	6.23e-07	1.36e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—lung cancer	6.22e-07	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—lung cancer	6.22e-07	1.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOA1—lung cancer	6.2e-07	1.35e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—lung cancer	6.19e-07	1.35e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—lung cancer	6.19e-07	1.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—lung cancer	6.19e-07	1.35e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—lung cancer	6.18e-07	1.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—lung cancer	6.18e-07	1.35e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—lung cancer	6.18e-07	1.35e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—lung cancer	6.16e-07	1.34e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—lung cancer	6.14e-07	1.34e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—lung cancer	6.14e-07	1.34e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—lung cancer	6.08e-07	1.33e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CREBBP—lung cancer	6.08e-07	1.33e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—lung cancer	6.03e-07	1.32e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—lung cancer	6.02e-07	1.32e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—lung cancer	6.01e-07	1.31e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—lung cancer	6.01e-07	1.31e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—lung cancer	6.01e-07	1.31e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—lung cancer	5.99e-07	1.31e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—lung cancer	5.95e-07	1.3e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	5.94e-07	1.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—lung cancer	5.87e-07	1.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—lung cancer	5.87e-07	1.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—lung cancer	5.87e-07	1.28e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—lung cancer	5.87e-07	1.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—lung cancer	5.87e-07	1.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—lung cancer	5.85e-07	1.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—lung cancer	5.83e-07	1.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—lung cancer	5.82e-07	1.27e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—lung cancer	5.81e-07	1.27e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EGF—lung cancer	5.8e-07	1.27e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—lung cancer	5.8e-07	1.27e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—lung cancer	5.76e-07	1.26e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—EP300—lung cancer	5.74e-07	1.25e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—lung cancer	5.73e-07	1.25e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—lung cancer	5.72e-07	1.25e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—lung cancer	5.71e-07	1.25e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—lung cancer	5.69e-07	1.24e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—lung cancer	5.67e-07	1.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—lung cancer	5.66e-07	1.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—lung cancer	5.66e-07	1.24e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—lung cancer	5.66e-07	1.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—lung cancer	5.62e-07	1.23e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—lung cancer	5.62e-07	1.23e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—STK11—lung cancer	5.61e-07	1.23e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGF—lung cancer	5.59e-07	1.22e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—POMC—lung cancer	5.59e-07	1.22e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—lung cancer	5.59e-07	1.22e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—lung cancer	5.58e-07	1.22e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—lung cancer	5.57e-07	1.22e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—lung cancer	5.55e-07	1.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EP300—lung cancer	5.55e-07	1.21e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EP300—lung cancer	5.53e-07	1.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—lung cancer	5.52e-07	1.21e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—lung cancer	5.51e-07	1.2e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—lung cancer	5.49e-07	1.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6R—lung cancer	5.45e-07	1.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREBBP—lung cancer	5.44e-07	1.19e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—lung cancer	5.41e-07	1.18e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—lung cancer	5.4e-07	1.18e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—lung cancer	5.39e-07	1.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—POMC—lung cancer	5.39e-07	1.18e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—lung cancer	5.38e-07	1.17e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—lung cancer	5.37e-07	1.17e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—lung cancer	5.37e-07	1.17e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—lung cancer	5.36e-07	1.17e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—lung cancer	5.35e-07	1.17e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—lung cancer	5.32e-07	1.16e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—EP300—lung cancer	5.3e-07	1.16e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6R—lung cancer	5.25e-07	1.15e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—lung cancer	5.25e-07	1.15e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—lung cancer	5.25e-07	1.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREBBP—lung cancer	5.25e-07	1.15e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—lung cancer	5.2e-07	1.14e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAP2K1—lung cancer	5.2e-07	1.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—lung cancer	5.2e-07	1.13e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—lung cancer	5.19e-07	1.13e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—lung cancer	5.18e-07	1.13e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—lung cancer	5.18e-07	1.13e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—lung cancer	5.17e-07	1.13e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—lung cancer	5.17e-07	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—lung cancer	5.16e-07	1.13e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—lung cancer	5.15e-07	1.12e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—lung cancer	5.14e-07	1.12e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EP300—lung cancer	5.1e-07	1.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAT—lung cancer	5.06e-07	1.1e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—lung cancer	5.05e-07	1.1e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—lung cancer	5.02e-07	1.1e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—lung cancer	5.02e-07	1.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAP2K1—lung cancer	5.01e-07	1.09e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—lung cancer	4.98e-07	1.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—lung cancer	4.98e-07	1.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—lung cancer	4.97e-07	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—lung cancer	4.97e-07	1.08e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—lung cancer	4.97e-07	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—lung cancer	4.96e-07	1.08e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—lung cancer	4.95e-07	1.08e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—lung cancer	4.95e-07	1.08e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—lung cancer	4.95e-07	1.08e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—lung cancer	4.83e-07	1.06e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—lung cancer	4.83e-07	1.05e-05	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—lung cancer	4.79e-07	1.04e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—lung cancer	4.77e-07	1.04e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—lung cancer	4.77e-07	1.04e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—lung cancer	4.74e-07	1.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—lung cancer	4.73e-07	1.03e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—lung cancer	4.71e-07	1.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—lung cancer	4.64e-07	1.01e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—lung cancer	4.64e-07	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—lung cancer	4.62e-07	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—lung cancer	4.62e-07	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—lung cancer	4.61e-07	1.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RAF1—lung cancer	4.61e-07	1.01e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—lung cancer	4.59e-07	1e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—lung cancer	4.57e-07	9.98e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—lung cancer	4.57e-07	9.97e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—lung cancer	4.56e-07	9.96e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1A1—lung cancer	4.53e-07	9.88e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—lung cancer	4.5e-07	9.82e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—lung cancer	4.5e-07	9.82e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ERCC2—lung cancer	4.49e-07	9.8e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—lung cancer	4.47e-07	9.75e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—lung cancer	4.46e-07	9.73e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—lung cancer	4.45e-07	9.72e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—lung cancer	4.45e-07	9.71e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RAF1—lung cancer	4.44e-07	9.7e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—lung cancer	4.4e-07	9.6e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—lung cancer	4.39e-07	9.59e-06	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—lung cancer	4.35e-07	9.5e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—lung cancer	4.34e-07	9.48e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—lung cancer	4.34e-07	9.47e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—lung cancer	4.34e-07	9.47e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—lung cancer	4.32e-07	9.44e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—lung cancer	4.3e-07	9.38e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—lung cancer	4.26e-07	9.31e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—lung cancer	4.24e-07	9.26e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—lung cancer	4.17e-07	9.1e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—EP300—lung cancer	4.14e-07	9.04e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—lung cancer	4.14e-07	9.04e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—lung cancer	4.13e-07	9.02e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—lung cancer	4.11e-07	8.98e-06	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—lung cancer	4.11e-07	8.97e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—lung cancer	4.1e-07	8.96e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—lung cancer	4.09e-07	8.93e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—lung cancer	4.06e-07	8.86e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—lung cancer	4.03e-07	8.8e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—lung cancer	4.02e-07	8.78e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—lung cancer	3.99e-07	8.71e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—lung cancer	3.98e-07	8.69e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—lung cancer	3.97e-07	8.66e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—lung cancer	3.93e-07	8.57e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—lung cancer	3.92e-07	8.55e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—lung cancer	3.91e-07	8.54e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—lung cancer	3.9e-07	8.51e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—lung cancer	3.89e-07	8.49e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOA1—lung cancer	3.88e-07	8.48e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—lung cancer	3.88e-07	8.48e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—lung cancer	3.87e-07	8.46e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—lung cancer	3.8e-07	8.29e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—lung cancer	3.79e-07	8.28e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—lung cancer	3.78e-07	8.26e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—lung cancer	3.78e-07	8.24e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—lung cancer	3.77e-07	8.23e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—lung cancer	3.76e-07	8.2e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—lung cancer	3.76e-07	8.2e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—lung cancer	3.75e-07	8.18e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EP300—lung cancer	3.71e-07	8.1e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—lung cancer	3.63e-07	7.93e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—lung cancer	3.62e-07	7.91e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—lung cancer	3.62e-07	7.9e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—lung cancer	3.61e-07	7.87e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EP300—lung cancer	3.57e-07	7.8e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—lung cancer	3.54e-07	7.74e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—lung cancer	3.51e-07	7.67e-06	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—lung cancer	3.49e-07	7.63e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—lung cancer	3.48e-07	7.59e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—lung cancer	3.48e-07	7.59e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—lung cancer	3.47e-07	7.57e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—lung cancer	3.47e-07	7.57e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—lung cancer	3.47e-07	7.57e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—lung cancer	3.38e-07	7.39e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—POMC—lung cancer	3.37e-07	7.37e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—lung cancer	3.35e-07	7.32e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—lung cancer	3.35e-07	7.32e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—lung cancer	3.34e-07	7.3e-06	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—lung cancer	3.34e-07	7.3e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—lung cancer	3.34e-07	7.29e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—lung cancer	3.32e-07	7.25e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CREBBP—lung cancer	3.29e-07	7.18e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—lung cancer	3.23e-07	7.05e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—lung cancer	3.2e-07	6.99e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—lung cancer	3.2e-07	6.99e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—lung cancer	3.12e-07	6.8e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—lung cancer	3.11e-07	6.8e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—lung cancer	3.08e-07	6.73e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—lung cancer	3.08e-07	6.72e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—lung cancer	3.06e-07	6.69e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—lung cancer	3.05e-07	6.65e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—lung cancer	2.99e-07	6.52e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—lung cancer	2.88e-07	6.28e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—lung cancer	2.74e-07	5.99e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—lung cancer	2.72e-07	5.93e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—lung cancer	2.69e-07	5.88e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—lung cancer	2.65e-07	5.79e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—lung cancer	2.64e-07	5.77e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—lung cancer	2.56e-07	5.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—lung cancer	2.54e-07	5.54e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—lung cancer	2.5e-07	5.46e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—lung cancer	2.45e-07	5.34e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—lung cancer	2.43e-07	5.3e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—lung cancer	2.35e-07	5.12e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—lung cancer	2.34e-07	5.11e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—lung cancer	2.24e-07	4.89e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—EP300—lung cancer	2.24e-07	4.89e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—lung cancer	2.16e-07	4.71e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—lung cancer	1.66e-07	3.62e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—lung cancer	1.35e-07	2.95e-06	CbGpPWpGaD
